Feed BMY
BM

Bristol-Myers Squibb

BMY · NYSE

$62.89 +2.26% (+$1.39)
1M -5.59%
Market Cap $125.6B
P/E Ratio 13.53x
Div. Yield 4.08%
ROE 46.75%

Bulios Fair Price

$57.14

9.1% downside

Trenutna cena

$62.89

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica BMY trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Strong
7/9
Valuation
80 /100
Cheap
P/B 5.63x
P/S 2.55x
P/E 13.53x
Growth
31 /100
Declining
Book val. growth 15.90%
FCF growth 2.44%
EPS growth 5.36%
Profitability
100 /100
Strong
FCF margin 23.26%
Op. margin 28.27%
Gross margin 70.16%
Quality
83 /100
Excellent
Asset turnover 0.56x
ROA 10.59%
ROIC 15.47%
Debt
54 /100
Moderate
Net debt/EBITDA 2.06x
Int. coverage 7.88x
Debt/Equity 1.93x
Stability
35 /100
Moderate
Profitable years 1
EPS volatility 198.26%
Beta 0.23x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o BMY
Online

O podjetju

Bristol-Myers Squibb Company (BMY) is an American pharmaceutical company with a global reach. The company specializes in research, development, and manufacturing of drugs and biological products for the treatment of various diseases. Bristol-Myers Squibb focuses its efforts on the treatment of cancer, cardiovascular diseases, immune disorders, and other serious conditions. The company is known for its innovative medications that bring significant medical benefits to patients. Bristol-Myers Squibb has a wide range of drugs on the market, and its products are distributed worldwide. The company also has an active research program aimed at discovering new drugs and therapeutic approaches. Bristol-Myers Squibb Company (BMY) shares are an attractive choice for investors who follow the pharmaceutical sector and seek investment opportunities in a renowned pharmaceutical company with a focus on innovative treatment methods.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Christopher Boerner

Employees

32,500

Headquarters

Princeton

Prihajajoči dogodki

02 OKT.

Ex-Dividend

Ex-dividend date

5d
29 OKT.

Earnings

Upcoming earnings report

32d
02 NOV.

Dividend Payment

Datum plačila

36d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.